Archive · 23 Jul 2026
Cipla Reports Q1FY27 Results, Expects US Sales Growth
Cipla, a big medicine company, recently shared its financial results for the first three months of the fiscal year.
They made less profit this time compared to last year, mainly because two important medicines were not available.
However, the company is hopeful about the future.
They expect to sell more medicines in the US soon, especially some new ones they are working on.
Their business in India is doing well, growing by 12%.
The company is also preparing for possible changes in the US market, like new rules about medicines.
Overall, they are planning to do better in the coming months.
Cipla's net profit dipped 39% YoY to ₹789 crore due to the absence of key products.
Revenue grew marginally by 2% to ₹7,119 crore.
Ebitda declined 33% to ₹1,192 crore, with margins shrinking from 25.6% to 16.7%.
India business revenue grew 12% YoY to ₹3,452 crore, accounting for nearly half of overall revenues.
US business revenue was $162 million, with expectations of sequential growth driven by new product launches.
- Who
- Cipla, a global pharmaceutical company
- What
- Reported Q1FY27 financial results with a 39% dip in net profit but expects US sales growth
- When
- Results announced on Thursday, Q1FY27
- Where
- Global operations with significant focus on the US and India
- Why
- Due to the absence of key products and softer US sales, but anticipates growth from new product launches
Optimistic Outlook
Current Financial Challenges
Future Growth Prospects
Optimistic Outlook
Cipla expects sequential sales momentum in the US driven by new product launches and approvals, particularly in respiratory assets and peptides.
Current Financial Challenges
Current quarter saw a 39% dip in net profit due to the absence of key products like lenalidomide and lanreotide.
Market Strategy
Optimistic Outlook
The company is optimistic about its pipeline, including significant launches and a promising peptide opportunity.
Current Financial Challenges
The US market faces potential challenges with phased tariffs on generic products starting in 2028, which could impact operations.
- Net Profit
- ₹789 crore (39% decrease YoY)
- Revenue
- ₹7,119 crore (2% increase YoY)
- Ebitda
- ₹1,192 crore (33% decrease YoY)
- Margins
- 16.7% (down from 25.6%)
- India Business Revenue
- ₹3,452 crore (12% increase YoY)
- US Business Revenue
- $162 million
- Full-Year Ebitda Guidance
- 18.5-20%
- US Sales Run Rate
- $1 billion by FY27 end